According to DelveInsight’s latest report, “Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast – 2034,” the global Paroxysmal Nocturnal Hemoglobinuria (PNH) market is expected to witness notable expansion during the forecast period. The report provides a comprehensive analysis of disease epidemiology, treatment patterns, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The study highlights historical data and future projections, offering detailed insights into market size, drug uptake, evolving treatment paradigms, and epidemiological trends across the seven major markets (7MM).
Get a Free sample for the Paroxysmal Nocturnal Hemoglobinuria Market Report:
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
Key Highlights from the Paroxysmal Nocturnal Hemoglobinuria Market Report
- The Paroxysmal Nocturnal Hemoglobinuria market was valued at approximately USD 1,141 million in 2023 and is projected to grow at a strong CAGR throughout the 2020–2034 forecast period.
- In December 2025, South Korea’s Ministry of Food and Drug Safety approved Piascai (crovalimab), developed by Roche, for the treatment of PNH in adults and pediatric patients aged 12 years and above weighing at least 40 kg. This marked the first pediatric approval for the therapy.
- In September 2025, Argo Biopharmaceutical received IND approval from China’s NMPA to initiate a Phase II trial of BW-40202, an siRNA therapy targeting complement factor B for PNH and other complement-mediated disorders.
- Novartis, in June 2025, reported positive data from the Phase 3B APPULSE-PNH trial, evaluating oral iptacopan (Fabhalta) in patients transitioning from anti-C5 therapies.
- NovelMed Therapeutics announced encouraging interim Phase II results for ruxoprubart (NM8074) in May 2025, demonstrating transfusion avoidance, improved hemoglobin levels, and favorable safety outcomes.
- In December 2024, Omeros Corporation presented positive Phase II data for zaltenibart (OMS906) at the ASH Annual Meeting, supporting its advancement into Phase III trials in early 2025.
Regional Paroxysmal Nocturnal Hemoglobinuria Market Insights
- The United States accounted for the largest share in 2023, with a market size of approximately USD 845.6 million, driven by high diagnosis rates and early adoption of novel therapies.
- The combined EU4 and UK market reached nearly USD 480.1 million, representing around 34% of total 7MM revenue, with the UK leading the region.
- Japan’s PNH market was valued at about USD 88.5 million in 2023 and is expected to grow steadily through 2034.
To Know in detail about the Paroxysmal Nocturnal Hemoglobinuria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Paroxysmal Nocturnal Hemoglobinuria Market Forecast
Paroxysmal Nocturnal Hemoglobinuria Epidemiology Overview
DelveInsight estimates that approximately 12,485 diagnosed prevalent Paroxysmal Nocturnal Hemoglobinuria cases were recorded across the 7MM in 2023, with prevalence expected to rise by 2034. The US reported the highest number of cases, followed by the UK and Germany. Gender-based analysis indicates a higher prevalence among females compared to males.
Paroxysmal Nocturnal Hemoglobinuria Pipeline and Competitive Landscape
The Paroxysmal Nocturnal Hemoglobinuria treatment pipeline includes several promising candidates such as pozelimab, OMS906, iptacopan, and ruxoprubart, reflecting growing innovation beyond traditional C5 inhibitors. Key industry players include AstraZeneca (Alexion), Hoffmann-La Roche, Novartis, Regeneron, Apellis Pharmaceuticals, Omeros Corporation, BioCryst Pharmaceuticals, and NovelMed Therapeutics, among others.
Paroxysmal Nocturnal Hemoglobinuria Market Outlook
The Paroxysmal Nocturnal Hemoglobinuria market is expected to expand significantly due to increasing disease awareness, improved diagnostic rates, and the launch of multiple late-stage pipeline therapies. Ongoing innovation in complement pathway modulation is anticipated to reshape treatment standards and improve long-term outcomes for PNH patients.
To know more about Paroxysmal Nocturnal Hemoglobinuria companies working in the treatment market, visit @ Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Therapeutic Assessment
About DelveInsight
DelveInsight is a leading healthcare business consulting and market research firm dedicated exclusively to the life sciences sector. The company partners with pharmaceutical and biotech organizations to deliver end-to-end solutions that enhance performance, support strategic decision-making, and drive sustainable business growth through data-driven insights and practical consulting expertise.
